A comparison of peripheral blood stem cell collection outcomes for multiple myeloma; mobilization matters in the era of IMiD induction

Collection of peripheral blood stem cells (PBSCs) for autologous cell transplant (ASCT) requires mobilization from the bone marrow. There is variation in choice; during COVID-19 pandemic BSBMT&CT guidelines recommended using granulocyte-colony stimulating factor (G-CSF) alone to minimize use chemotherapy. We report on impact regimen collection, and whether IMiD-containing induction therapy impacts consequently engraftment times 83 patients undergoing ASCT at Leeds Teaching Hospitals. Cyclophosphamide plus G-CSF (cyclo-G) yielded more CD34+ (8.94 vs. 4.88 ×106/kg, p = < 0.0001) over fewer days (1.6 2.4 days, 0.007), required doses salvage Plerixafor than only (13.6% 35%, 0.0407). impaired all these factors. > 8×106/kg were frequent with Cyclo-G (62% 11%, 0.0001), including those receiving IMiD 1st line (50% 13.3%, 0.0381). Note that 92.6% IMiD-free inductions mobilized Cyclo-G. The novel agents used modern regimens (e.g Daratumumab) have been shown impair yields, increasing importance optimizing first instance. Furthermore, as cellular therapies become established management multiple myeloma emerging data highlights potential benefits top up haematological toxicities therapies. Our findings support re-adoption gold standard optimize PBSC harvesting ensure sufficient subsequent ASCTs.